Baird's Investment Banking Group is pleased to announce the following transaction:

November 2021
Apellis Pharmaceuticals, Inc.
Follow-on Offering
Baird served as lead manager on this offering
$403.000 Million

Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10,062,500 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $402.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. The offering included the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares of common stock.

Apellis is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. A leader in targeted C3 therapies, Apellis aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology and neurology. Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

For additional information about this transaction, please contact:

Derrick Li +1-516-606-6763
Lance Lange +1-414-765-7079
Michael Kim +1-312-609-4482
Matt Gailey +1-414-765-1458